Good morning, and welcome to our 28th meeting of the Coordinating Board in New York. We are almost 10 months into 2016 and this year is of crucial importance. This is the first year of the Global Plan to End TB 2016-2020 and we need to impose the rhythm and intensity of efforts that will lead us to achieving our targets. I feel that we are going in the right direction.

The launch of the Global Plan at the last Board meeting has meant that we have worked this year to continue to get it endorsed at the highest political levels and discussed worldwide. In June, in New York, at the UN High-Level Meeting on HIV/AIDS, the Political Declaration adopted by Heads of State at the meeting included a commitment to funding and implementing the targets in the Global Plan and the Plan’s 90-(90)-90 targets. For this, we are very grateful for the work with our partner from UNAIDS in making this happen, and in looking forward to our future collaboration to increase the scale up of TB/HIV integration.

In Addis Ababa, just last month, during a special TB session led by our Chaire, the African Ministers of Health endorsed the Global Plan, the targets and the African Framework for ending TB with a commitment to increase domestic TB allocations. This is a big step forward, but the first in front of very many to come.

To accelerate our efforts and to bend the curves of TB incidence and mortality as we should, we need to be smart and innovative. I have hope that we will be able to discover, fund and scale innovative approaches in TB detection and care now that we announced the replenishment of TB REACH through a five-year award of CA$ 85 million from the Government of Canada. The Bill & Melinda Gates Foundation and the Indonesia Health Fund have given supplementary funding towards TB REACH for the first time and, with the team working hard on its implementation, we hope to have selected our new grantees by the end of the year and move forward at a sustained pace.

Our GDF team – in partnership
with other partners, especially the Global Fund Secretariat and under the leadership of country programmes worked hard, with dedication, professionalism and flexibility, and ensured that all commodities are supplied in a timely fashion and no stock outs are recorded, that anti-TB medicines are available at the most competitive prices and that the new drugs and regimens are available to early implementers.

We all agree that nothing can be achieved unless we put the people affected by TB at the center of all work and efforts, and we accelerated the work we do in this area by our Challenge Facility work and on ensuring that the gender and human rights centered interventions are becoming the norm for TB programmes. We continued to support and encourage the work with vulnerable groups and key populations, to roll out the gender assessment tool and support meetings, capacity building and interaction of people affected by TB.

All this is good, but we have a long way to go to reach the 2020 targets of the Global Plan in order to ensure we are on track to end TB by 2030. We will very carefully monitor the commitments we made in the Global Plan – the paradigm shift, the financial investments, the 90-90-90 targets, the TB policies, the R&D investments. But the efforts and the work needed to scale up tremendously in countries and we must ensure that we all work in syncrhonization and with amazing coordination to make a difference.

We have some good opportunities now, with a very good replenishment of the Global Fund, availability of new drugs and new regimens and a renewed spirit and mindset. What we need to give a full push is a very high level discussion of heads of states and governments about TB. And this is the vision of our Chair, Minister Motsoaledi – a UN high level meeting on TB in 2017. I think we have all learned from him to be bold, dynamic, fresh and one step ahead of times so I am fully onboard to work hard, together with our Secretariat and partners to make this happen in the year to come. And we hope we can count on your support as well.

I am grateful to work under your leadership, especially the extraordinary leadership of Minister Motsoaledi and Joanne Carter over the past three years and blessed to have them for another three-year term. I am grateful to work with you all in the Board – as we are all working under the same goals and we are all in this together. It is not an easy environment we operate now, but if we keep in our hearts that the work we do serves all those suffering from TB and that we are accountable for saving their lives, we will end TB.

We will do it.

The KPIs will be presented tomorrow to the Coordinating Board for approval.
OUR ACHIEVEMENTS AT A GLANCE

1. **1518 ACTIVE PARTNERS**
   - A highly committed and highly ambitious secretariat team

2. **UNOPS INTERNAL AUDIT**
   - Highest possible rating of achievement

3. **THE PARADIGM FOR HUMANS’ RIGHTS AND LAW**
   - 20 companies have joined the private sector constituency
   - Now counts over 120 members

4. **TB PEOPLE**
   - Launch of the very first network of people with experience of TB in the Eastern Europe and Central Asia region

5. **GDF CONDUCTED 11 MONITORING, TECHNICAL ASSISTANCE MISSIONS TO SUPPORT COUNTRIES**

6. **Global Plan to End TB 2016-2020**
   - The Paradigm Shift launched

7. **GLOBAL PLAN TO END TB**
   - From January to June 2016, 64 orders have been placed with suppliers and 149 shipments delivered to countries (total value of US $13.9 millions)

8. **GLOBAL PLAN TO END TB REACH DEVELOPMENT**
   - Developed with the Global Fund Secretariat on TB
   - End TB

9. **ZERO TB INITIATIVE LAUNCHED**
   - First ever compilation of survivor stories published

10. **TB JOURNEYS**
    - First ever compilation of survivor stories published

11. **STOP TB PARTNERSHIP SECRETARIAT KPI’S 2016-2020**
    - 2016-2020 operational strategy developed
    - Kochon Prize awards

12. **GLOBAL PLAN TO END TB ENDORSED BY GLOBAL AND NATIONAL LEADERS AT THE 2015 UNION CONFERENCE, UN High Level Meeting on HIV/AIDS in New York, WHO Regional Committee Africa and WHO Regional Committee for SEARO**

13. **MINI GUIDES FOR KEY POPULATIONS LAUNCHED FOR:**
    - Children, drug users, miners, mobile populations including migrants, refugees and internally displaced persons, prisoners and incarcerated populations, urban slum dwellers, rural poor, people living with HIV, and health-care workers

14. **RED ARROW LAUNCHED**
    - And rolled-out with more than 18,000 pins distributed so far

15. **GDF JUMPSTARTS ACCESS TO NEW DRUGS**
    - Delamanid and bedaquiline - with innovative public-private partnerships

16. **FRANCOPHONE MEMBERS OF PARLIAMENT**
    - Sign cooperation agreement to lead on fight against TB

17. **END TB**
    - Launched and piloted through Round 7 of the Challenge Facility for Civil Society

18. **GLOBAL TB CAUCUS**
    - Hosted by Stop TB Partnership Secretariat - more than 1400 Parliamentarians from 130 countries

    - And a linguistic network covering Francophone nations

20. **KEY POPULATIONS**
    - Gender assessment tool for national HIV and TB responses launched and piloted

21. **OUR GLANCE AT ACHIEVEMENTS**
    - First ever compilation of survivor stories published
    - Over 10,000 twitter followers (From 4680 in August 2014)
    - Over 10,000 ‘likes’ on Facebook (From 4202 in January 2014)
    - Mou with Global Fund signed
    - Weekly work with the Global Fund secretariat on tb situation room
    - Preliminary work on innovative financing and solutions to address barriers
    - Resource needs for tb developed with the Global Fund for the next funding cycle
    - Additional funding from PSC members mobilized
    - Developing a framework for key populations and sub-national disaggregated data analysis and use
    - Representing the TB community voice on Global Fund processes and committees

22. **TB REACH DEVELOPING AN MOU WITH THE GLOBAL FUND**
    - On how to scale-up and incorporate learnings from TB REACH projects into Global Fund grants

23. **High level missions in India, Indonesia, Nigeria**
    - Concrete outcomes on scaling up TB interventions and maximizing impact of Global Fund investments

24. **Highly ambitious UNOPS internal audit**
    - Highest possible rating of achievement

25. **KOCHON PRIZE AWARDS**
    - Launched and piloted through Round 7 of the Challenge Facility for Civil Society

26. **GDF JUMPSTARTS ACCESS TO NEW DRUGS**
    - Delamanid and bedaquiline - with innovative public-private partnerships

27. **GLOBAL FUND TECHNICAL ASSISTANCE**
    - And highly ambitious UNOPS internal audit

28. **A HUGELY COMMITTED AND HIGHLY AMBITIOUS SECRETARIAT TEAM**
    - Highest possible rating of achievement

As of September 2016, the current number of patients on bedaquiline under program conditions is 5234. GDF has delivered 1722 bedaquiline patient treatments to 37 countries via the USAID bedaquiline donation program, and is currently processing orders for more than 2900 bedaquiline patient treatments to be delivered over the coming months.
Global Plan to End TB 2016-2020: The Paradigm Shift launched and endorsed by global and national leaders

Minister Motsoaledi and I travelled to Japan in January for the International Conference on Universal Health Coverage and the Global Fund's Fifth Replenishment preparatory meeting. During a high-level panel session with Mr. Bill Gates, Minister Motsoaledi highlighted the need for innovations in addressing TB and HIV and showcased how the Partnership's TB REACH program was driving innovations on the frontlines. We also met with political leaders in Japan to outline the importance of their continued leadership on TB as Chair of the G7 Group of Countries.

In February, our advocacy efforts on TB and mining came to fruition when The Global Fund and a group of ten Southern African countries signed a landmark $30 million grant to pioneer innovative models to reduce high rates of TB in the mining sector. Miners in the Southern Africa region have some of the highest rates of TB infection in the world and the Partnership had a driving role in advancing this issue, starting in 2011 when Minister Motsoaledi brought the issue to the attention of Heads of States in the region.

Minister Motsoaledi and I travelled to Washington to mark World TB Day on 24 March and met with leaders in the US Government to thank them for their continued leadership in global TB efforts. Joined by our Board Vice-Chair Dr. Joanne Conner and Board member Ms. Cheri Vincent, we met with Assistant Administrator for Global Health, USAID, Ambassador Deborah Birx, U.S. Global AIDS Coordinator, and Dr. Paul Farmer, co-founder of Partners in Health. In May, the Government of Canada announced a renewed investment of CAS 85 million for the Stop TB Partnership's TB REACH initiative from 2016-2020. The Bill & Melinda Gates Foundation also pledged US$ 7 million to fund TB REACH and The Indonesia Health Fund pledged US $1.5 million to support TB REACH's Indonesian efforts. Minister Motsoaledi and other Board members played a critical role in making the case for these investments, which will ensure TB REACH continues its critical work in supporting new innovations in the fight against TB.

On the occasion of the Sixth-Ninth World Health Assembly in Geneva, the Secretariat in collaboration with the Permanent Mission of India and the World Intellectual Property Organization (WIPO), organized a cultural event and gala dinner to “Unite to End TB” on 21 May at WIPO HQ. The event was a great success with a turnout of more than 180 guests including Ministers, Ambassadors from 16 countries and heads of multilateral organizations.

The Partnership coordinated the TB community’s engagement in the lead up to the 2016 UN High-Level Meeting on HIV/AIDS to ensure strong commitments for joint action on HIV/AIDS and TB. In April, we organized a side-event with UNAIDS at the Civil Society Hearings for the High-Level Meeting. Stop TB Partnership Coordinating Board members Mr. Austin Obufoama and Ms. Thekiso Phumzile called on over 100 attendees from civil society to unite in the response to HIV/AIDS and TB, and ensure TB was included as a key priority.

Strong engagement by Minister Motsoaledi and other Board members led to TB being included as a top priority in the outcomes of the UN High-Level Meeting on HIV/AIDS held in June 2016. The Political Declaration adopted...
High level advocacy missions to countries

Advocating for the implementation of the Global Plan and scale-up of TB interventions

In March, I and the Deputy Executive Director attended the World TB Day event in India, where I met with the Honourable Minister JP Nadda and senior government officials, civil society partners, and other stakeholders leading the fight against TB in India.

The Minister launched several new initiatives on TB in India, where I met with the Regional Director of WHO SEARO who expressed her commitment and support for a new approach to scale up the TB response in the Region in order to achieve implementation of the WHO End TB Strategy and the Global Plan to End TB. During my visit and alongside the India event, WHO SEARO invited other countries in the Region who committed to fast track the TB responses in their countries in line with the new agenda to end TB as an epidemic. Our team has since then engaged with WHO SEARO to create opportunities for further advocacy and elevation of ambition levels of countries in the Region.

In April 2016, the Deputy Executive Director visited Mozambique and met with the Deputy Minister of Health as well as participated in a Global Fund convened meeting for countries in the Region. The Deputy Minister was made aware about the low absorption rate of the Global Fund TB grant and action points were discussed and agreed to speed up implementation.

In April, I travelled to Indonesia for a joint mission with the Global Fund to Fight AIDS, TB and Malaria. The main purpose was to have a discussion with the Minister of Health of Indonesia on the Global Fund TB grant and to ensure that funds are put to best use for TB affected people. It was a successful meeting, also for strengthening the relationships and engagement with the NTP manager and team as well as the most senior staff in the Ministry of Health. I also met with Mr. Anfini Panigoro, Chair of the Stop TB Partnership Indonesia, the Honourable Budi Yusuf, a Member of Parliament leading TB efforts among parliamentarians. The mission resulted in opportunities to strengthen TB efforts and align partners behind the Global Plan to End TB.

In May I travelled to Nigeria with Ambassador Eric Goosby, UN Special Envoy for TB to participate in the first National TB Conference organized by Stop TB Partnership and the Stop TB Partnership, which garnered major media coverage on television, radio, and print. We met with the Wife of the President, Her Excellency Mrs Aisha Muhammad Buhari, the Minister of Health, the Senate Committee on Health, the House Committee on AIDS, TB and Malaria, and other key groups engaged in TB efforts. I am grateful to our partners in Nigeria for their efforts to raise the political profile of TB, and especially the First Lady of Nigeria for her outstanding leadership.

In July, I joined Minister Motsoaledi in Durban, South Africa for the TB2016 Ministerial Meeting and AIDS 2016 conferences. Minister Motsoaledi delivered the Global Plan to End TB at both conferences where he spoke about the work of the Partnership and the Global Plan to End TB. I presented the Global Plan to End TB and the 90-90-90 targets were also endorsed. We also launched the Stop TB Campaign with MSF which asks countries to update their TB policies in line with global guidelines within 500 days. The launch featured a large wall poster map of the African TB Caucus, where the Global Plan to End TB and the 90-90-90 targets were endorsed. We also launched a special session on TB during the WHO AFRO Health Ministers Meeting. We presented the case for increased domestic investments in TB to the Ministers and outlined the actions needed to implement the paradigm shift called for in the Global Plan. We were delighted that the Ministers of Health endorsed a motion supporting the Global Plan to End TB, the 90-90-90 targets, and the need for increased domestic financing for TB.

I also undertook missions to key TB donor countries, including Japan, United States, Germany, France as well as the UK, in order to brief our key donors and partners on the work of the Stop TB Partnership, the Global Plan to End TB and the financial resources needed.

World TB Day 2016

This year’s World TB Day campaign ran under the strong and action-oriented tagline ‘Unite to End TB’.

As with previous years, the Secretariat led on the high level efforts through five consultative teleconferences with the Core Communications Partners to jointly decide on the theme. Partners working in TB from all over the globe chose this dynamic and unifying rallying call that allows for both strong mobilization on the ground and high level advocacy.

This campaign draws on the goals set out in the Global Plan to End TB, the roadmap to accelerating impact on the TB epidemic and reaching the targets of the WHO End TB Strategy. The Secretariat developed the set of campaign materials in the six official UN languages (English, French, Spanish, Arabic, Chinese and Russian). These were free to use and were available for download for local production through its website: http://stoptb.org/events/world_tb_day_2016/materials.asp
The ‘Unite to End TB’ theme was celebrated extensively and here are some of the highlights and ‘unusual’ actions undertaken by non-traditional actors:

**a. IN BARCELONA,** the city government illuminated the city hall in red and with the World TB Day logo.

**b. IN RIO DE JANEIRO,** the lighting of key monuments which were illuminated in red by Christo Redentor, the Moorish Castle of the Oswaldo Cruz Foundation and the Metropolitan Cathedral was dedicated to World TB Day at the initiative of the Ministry of Health.

**c. IN WASHINGTON D.C.,** global health leaders joined together to pledge their support to end TB by 2030 in a USAID-hosted event attended by over 400 people. USAID presented the TB Champion Award to Minister Motsoaledi for his leadership in fighting TB and success in scaling up TB efforts in South Africa. An award was also presented to Dr. Paul Farmer, co-founder of Partners in Health for the work that the organization has done treating TB and MDR-TB affected people and supporting the poor. Ambassador Jalil Abbas Jilani, Ambassador of Pakistan to the United States, accepted the third award on behalf of the Ministry of Health of Pakistan.

**d. THE PARTNERSHIP SUPPORTED PAULINA SINIATKINA,** a Russian TB survivor and artist through her ‘Hold Your Breath’ art exhibit which portrayed her experience with the disease and the stigma surrounding TB. The exhibit opened in Moscow on World TB Day. Mr. Timur Abdullaev, Community Representative on the Stop TB Partnership Coordinating Board, spoke at the opening on behalf of the Stop TB Partnership.

**e. IN GENEVA, SERVETTE FOOTBALL CLUB,** the city’s leading football club supported World TB Day by welcoming the Stop TB Partnership to their home match against FC Bretenrain on 24 March 2015. Before kick-off, the stadium’s giant screen displayed a World TB Day campaign advertisement developed by the Partnership. Secretariat staff were at the game to hand out Red Arrow pins to arriving football fans and answer questions about TB and the Partnership. Staff also collected donations from fans. The Secretariat also raised funds through the three canteens where the Secretariat is based over the lunch hours. Proceeds from both the football match and the canteens will go towards a special award that will be given to a deserving recipient at the October Liverpool Union Conference Stop TB Partnership Town Hall Meeting.

**f. MANY HIGH PROFILE PERSONALITIES MARKED WORLD TB DAY** with the former UK Prime Minister David Cameron and US Presidential Candidate Hillary Clinton taking to Twitter themselves on World TB Day. Other leaders such as Michel Sidibe, the famous actor Amitabh Bachchan, and UN Secretary-General Ban Ki-moon all tweeted through their official accounts.

**g. THIS YEAR’S WORLD TB DAY ALSO SAW UNPRECEDENTED SOCIAL MEDIA REACH,** especially on Twitter and Facebook. Through the #UniteToEndTB hashtag, we reached over 32 million people. The full report can be read here: http://bit.ly/2c9ht8u
Launch and the roll out of the Red Arrow

The Red Arrow was launched on the margins of the 46th Union World Conference on Lung Health in Cape Town, 4 December 2015.

It is a symbol for our solidarity towards a world without TB. The arrow represents our unwavering commitment to move forward with the mission until we reach the finish line to End TB.

The Red Arrow was worn at the community TB march by hundreds of people who marched the streets of Cape Town calling for leaders around the world to end TB. It was powerful to see how a symbol unified activists, political leaders, researchers and people affected by TB against a common cause.

We commissioned the production of over 20,000 Red Arrow pins and over the course of the last ten months, we have distributed nearly 18,000 Red Arrow pins to more than 400 partners. It has been given out to participants in major TB events around the globe.

The Red Arrow has featured prominently in this year’s World TB Day campaign materials – this includes on all the web and social media channels (Facebook, Twitter, Vimeo, Instagram), on posters, infographics, call to action logos, flyers, brochures and the community toolkit. The Red Arrow will continue to be a key feature on all World TB Day related activities for many years to come.

“My message to other people with TB is simple: take the treatment and be done with it. And then, after being cured, become an activist and help others with TB. We have to spread activism, just like TB is spreading through society. We have to make activism a disease. Once we get over TB, we cannot and we should not forget about it as if it was a bad dream. We have to remember the experience and support others.”

TIMUR ABDULLAEV
"TB Journeys"

Global TB Caucus

With the support of the new Secretariat hosted and supported by the Stop TB Partnership, the Global TB Caucus has developed rapidly and now has over 1400 Parliamentarians from more than 130 countries.

As of now, there are four regional networks, including the Asia Pacific network launched in 2015, the Americas regional network launched in March, followed by the European network in June and the Africa network in July. A linguistic network for French speaking countries was also launched in July. The regional networks work to coordinate the new national parliamentary groups which have been established in Georgia, Mozambique, Nepal, New Zealand, Sudan, and Australia, with over half a dozen further groups planned for the second half of the year.

The second Global TB Summit took place from 28 – 30 November 2016 in Cape Town, South Africa. Fifty parliamentarians from 30 countries met to discuss the future of the TB epidemic and what they could do, collectively and individually, to accelerate progress against the epidemic. At the Summit they endorsed the Global Plan to End TB 2016-2020, agreed to support...
the replenishment of the Global Fund, and to establish a formal Secretariat to support their work. Country parliamentarians from New Zealand secured the first pledge to the Global Fund for eight years. In Peru and the Philippines, the respective co-chairs of the Americas and Asia Pacific Caucuses successfully advanced new anti-TB legislation. Thanks to a concerned advocacy campaign, Argentina has committed to making MDR-TB a priority for the next meeting of South American Heads of State to drive towards the elimination of TB in the Americas. 

With support from RESULTS UK and Australia respectively, British and Australian parliamentarians helped secure GBP 1 billion and AUD 100 million for research and development for infectious diseases. Caucus members in more than 30 countries also sent a letter to their Heads of State requesting their support for a fully replenished Global Fund at the replenishment conference in Montreal, Canada in September.

In the remainder of the year and going into the period 2017-2020 the Global TB Caucus will focus on building support and pressure in priority countries. The network is seeking to establish groups of parliamentarians in high burden countries to work with civil society partners in achieving a sustainable political response to the disease.

Anti-Microbial Resistance (AMR)

The final recommendations of the Review on Antimicrobial Resistance (AMR) led by Lord Jim O’Neill and commissioned by the former UK Prime Minister David Cameron were released in May, warning that AMR infections such as drug-resistant TB will kill 10 million annually without an urgent expansion of new resources and funds.

The report provides a comprehensive action plan for the world to prevent drug-resistant infection and highlights drug-resistant TB as a cornerstone of the global AMR challenge, highlighting that one-quarter of the potential 10 million annual AMR deaths by 2050 outlined in the report could be caused by drug-resistant TB without urgent action, which equates to one MDR-TB death every 12 seconds. It notes that the TB drug development field suffers from a prolonged period of disinvestment by commercial product developers leaving a perilously thin pipeline of products under development.

The UN High-Level Meeting on AMR taking place 21 September will further boost attention to this issue and will be attended by several Heads of State. We are pleased to be partnering with the AMR Review on a high-level side event ahead of the high-level meeting taking place on 20 September, and will continue to work closely with key partners in the global AMR response.

The Stop TB Partnership and our UK partners worked closely with the review team and provided recommendations into the final report. Minister Mottakalidi and I met with Lord O’Neill in May during the World Health Assembly and our staff have worked closely with the AMR Review to ensure strong integration between the AMR and TB agendas.

The Stop TB Partnership and our UK partners worked closely with the review team and provided recommendations into the final report. Minister Mottakalidi and I met with Lord O’Neill in May during the World Health Assembly and our staff have worked closely with the AMR Review to ensure strong integration between the AMR and TB agendas.

The Stop TB Partnership and our UK partners worked closely with the review team and provided recommendations into the final report. Minister Mottakalidi and I met with Lord O’Neill in May during the World Health Assembly and our staff have worked closely with the AMR Review to ensure strong integration between the AMR and TB agendas.

From left: Minister Aaron Motsoaledi, Lord Jim O’Neill, Prof. Dame Sally Davies

The secretariat has also continued to grow its presence on Instagram and Vimeo and the team are continuing State-requested outreach of communication and dissemination with our partners by testing boundaries and being visible in the way we communicate. Comparatively in January 2014, the Stop TB Partnership’s Facebook page was at 4204 ‘likes’ and its Twitter feed had 6680 followers in August 2014.

The monthly Stop TB Partnership communications e-newsletter now reaches almost 18,000 stakeholders through our core mailing lists. It contains all of the Partnership’s top line news for the given month, news from our partners, key announcements, a calendar of important upcoming events, an opinion editorial, a consolidation of TB coverage in the media, new appointments and/or a recommended read for the month. Newsletters published in 2016 thus far can be found here: http://www.stoptb.org/newsletters/2016/default.asp

The Stop TB Partnership and MSF released the Out of Step 2015 report, a 24-country survey that tracked adoption of the latest TB policies, guidelines and tools across five areas: diagnosis and drug resistance testing, drug-sensitive TB (DS-TB) treatment regimens, multidrug-resistant treatment regimens, models of care, and regulatory frameworks. The results of this survey provide a snapshot of the world’s readiness to defeat the TB epidemic. As mentioned earlier, we launched the Stop Up for TB Campaign with MSF in Darbaran at TB2016, featuring a large wall poster map on countries’ TB policies. The Secretariat has now started work on the 2016 Out of Step report in partnership with MSF.

This will be summarized in four progress reports comprising (1) TB6 (2005-2015) and The Paradigm Shift, (2) Financing TB, (3) Monitoring TB Policies - Out of Step Report and (4) Monitoring TB Funding, which was released in October 2016 and shows that TB funding for R&D is still insufficient and a continued exit of pharmaceutical companies from TB R&D. The modest gains in TB research funding from 2005 to 2015 have stagnated in the five years since, and total funding for TB R&D has never exceeded USD 700 million per year – in 2014, TB R&D totaled USD 674 million, a decrease of USD 12 million from 2013. TAG has tracked global spending on TB R&D each year since 2005, measuring actual funding levels against the targets set forth in the previous Global Plan to Stop TB. The Secretariat is currently supporting TAG to develop the 2016 report on TB research funding which will form the baseline for the monitoring of the research part of the Global Plan to End TB 2016-2020.

The Stop TB Partnership and MSF released the Out of Step 2015 report, a 24-country survey that tracked adoption of the latest TB policies, guidelines and tools across five areas: diagnosis and drug resistance testing, drug-sensitive TB (DS-TB) treatment regimens, multidrug-resistant treatment regimens, models of care, and regulatory frameworks. The results of this survey provide a snapshot of the world’s readiness to defeat the TB epidemic. As mentioned earlier, we launched the Stop Up for TB Campaign with MSF in Darbaran at TB2016, featuring a large wall poster map on countries’ TB policies. The Secretariat has now started work on the 2016 Out of Step report in partnership with MSF.

This will be summarized in four progress reports comprising (1) TB6 (2005-2015) and The Paradigm Shift, (2) Financing TB, (3) Monitoring TB Policies - Out of Step Report and (4) Monitoring TB Funding, which was released in October 2016 and shows that TB funding for R&D is still insufficient and a continued exit of pharmaceutical companies from TB R&D. The modest gains in TB research funding from 2005 to 2015 have stagnated in the five years since, and total funding for TB R&D has never exceeded USD 700 million per year – in 2014, TB R&D totaled USD 674 million, a decrease of USD 12 million from 2013. TAG has tracked global spending on TB R&D each year since 2005, measuring actual funding levels against the targets set forth in the previous Global Plan to Stop TB. The Secretariat is currently supporting TAG to develop the 2016 report on TB research funding which will form the baseline for the monitoring of the research part of the Global Plan to End TB 2016-2020.

The Stop TB Partnership and MSF released the Out of Step 2015 report, a 24-country survey that tracked adoption of the latest TB policies, guidelines and tools across five areas: diagnosis and drug resistance testing, drug-sensitive TB (DS-TB) treatment regimens, multidrug-resistant treatment regimens, models of care, and regulatory frameworks. The results of this survey provide a snapshot of the world’s readiness to defeat the TB epidemic. As mentioned earlier, we launched the Stop Up for TB Campaign with MSF in Darbaran at TB2016, featuring a large wall poster map on countries’ TB policies. The Secretariat has now started work on the 2016 Out of Step report in partnership with MSF.

This will be summarized in four progress reports comprising (1) TB6 (2005-2015) and The Paradigm Shift, (2) Financing TB, (3) Monitoring TB Policies - Out of Step Report and (4) Monitoring TB Funding, which was released in October 2016 and shows that TB funding for R&D is still insufficient and a continued exit of pharmaceutical companies from TB R&D. The modest gains in TB research funding from 2005 to 2015 have stagnated in the five years since, and total funding for TB R&D has never exceeded USD 700 million per year – in 2014, TB R&D totaled USD 674 million, a decrease of USD 12 million from 2013. TAG has tracked global spending on TB R&D each year since 2005, measuring actual funding levels against the targets set forth in the previous Global Plan to Stop TB. The Secretariat is currently supporting TAG to develop the 2016 report on TB research funding which will form the baseline for the monitoring of the research part of the Global Plan to End TB 2016-2020.

The Stop TB Partnership and MSF released the Out of Step 2015 report, a 24-country survey that tracked adoption of the latest TB policies, guidelines and tools across five areas: diagnosis and drug resistance testing, drug-sensitive TB (DS-TB) treatment regimens, multidrug-resistant treatment regimens, models of care, and regulatory frameworks. The results of this survey provide a snapshot of the world’s readiness to defeat the TB epidemic. As mentioned earlier, we launched the Stop Up for TB Campaign with MSF in Darbaran at TB2016, featuring a large wall poster map on countries’ TB policies. The Secretariat has now started work on the 2016 Out of Step report in partnership with MSF.

This will be summarized in four progress reports comprising (1) TB6 (2005-2015) and The Paradigm Shift, (2) Financing TB, (3) Monitoring TB Policies - Out of Step Report and (4) Monitoring TB Funding, which was released in October 2016 and shows that TB funding for R&D is still insufficient and a continued exit of pharmaceutical companies from TB R&D. The modest gains in TB research funding from 2005 to 2015 have stagnated in the five years since, and total funding for TB R&D has never exceeded USD 700 million per year – in 2014, TB R&D totaled USD 674 million, a decrease of USD 12 million from 2013. TAG has tracked global spending on TB R&D each year since 2005, measuring actual funding levels against the targets set forth in the previous Global Plan to Stop TB. The Secretariat is currently supporting TAG to develop the 2016 report on TB research funding which will form the baseline for the monitoring of the research part of the Global Plan to End TB 2016-2020.

The Stop TB Partnership and MSF released the Out of Step 2015 report, a 24-country survey that tracked adoption of the latest TB policies, guidelines and tools across five areas: diagnosis and drug resistance testing, drug-sensitive TB (DS-TB) treatment regimens, multidrug-resistant treatment regimens, models of care, and regulatory frameworks. The results of this survey provide a snapshot of the world’s readiness to defeat the TB epidemic. As mentioned earlier, we launched the Stop Up for TB Campaign with MSF in Darbaran at TB2016, featuring a large wall poster map on countries’ TB policies. The Secretariat has now started work on the 2016 Out of Step report in partnership with MSF.
in the context of identifying international and domestic donors, recent funding trends, allocation and disbursement of funds as well as financial gaps and needs in countries. Both reports will be launched on World TB day and will form the basis for tracking progress of countries in alignment with the Global Plan to End TB 2016–2020.

Kochon Prize

The 2015 Kochon Prize theme, voted on and chosen by Stop TB partners, focused on unrecognized/unsung heroes working in TB.

Challenger Facility for Civil Society

Round 7 of the Challenge Facility for Civil Society received 482 proposals – 10 were approved for funding by an independent selection committee.

Challenge Facility for Civil Society

Round 7 of the Challenge Facility for Civil Society received 482 proposals – 10 were approved for funding by an independent selection committee.

Central Asia and 2 from Asia Pacific) were recommended for funding. The grantee and respective country profiles can be found here: [http://www.stoptb.org/global/awards/cfcs/about.asp](http://www.stoptb.org/global/awards/cfcs/about.asp).

Grants are being implemented in two phases. To implement Phase II activities, grantees, using tools developed by the Stop TB Partnership, conducted exercises to map the community response, the actors and the gaps in geographic and service delivery, according to the six core components of a functional community system with a focus on key populations. Given that the focus of Round 7 is to build functional networks, a novel evaluation framework using both qualitative and quantitative methodologies is being implemented. The process and calibre of collaboration is being evaluated. Independent baseline assessments have taken place in all ten countries and end of project assessments will take place in the last two months of grant implementation. Phase I for all grantees is coming to an end, and project deliverables (Directory of CSOs, Matrices of Community Response, Gap in Services and Populations documented, CSO network identified, and Network Engagement Plan) will be awarded on 26 October 2016 in Liverpool in advance of the 46th Union World Conference on Lung Health: [http://www.stoptb.org/global/awards/kochon/awardees/2015.asp](http://www.stoptb.org/global/awards/kochon/awardees/2015.asp).

In 2016, the theme for the Kochon Prize remains the same. Since the call was announced, we have received 22 nominations representing 17 countries. We have been working with the Kochon committee and the winners have been identified. The prize will be awarded on 26 October 2016 in Liverpool in advance of the 47th Union World Conference on Lung Health.

Engaging, supporting and strengthening communities

The Stop TB Partnership Secretariat is supporting and funding several streams of work in order to ensure that communities, people affected by TB and advocates are central to all efforts and programmes.

Most of this work is currently done through the funding received from the Global Fund under the Global Fund Technical Assistance Agreement and in-kind support of several staff members of the Secretariat. We are proud of the work and achievements so far, under very limited resources.

The main scope of all this work is to ensure that the TB NSP and further Global Fund applications aim at strengthening communities, properly address key populations and vulnerable groups, and include gender and human rights sensitive approaches.

It highlighted the critical role health workers, community workers and volunteers play both in the developed world as well as in some of the poorest countries plagued with unimaginable shortages of health services and limited access to TB care. There were 25 nominations received representing 19 countries, and three winners were selected: ASPAT-Peru, a community based non-profit organization founded by a former TB patient; Naomi Wanjiru, a nurse who has, for the past six years, managed a clinic in Central Kenya attending to TB and HIV/AIDS patients while faced with her own personal ordeal with TB; and, Natalya Vezhnina, a medical doctor who has made an immense contribution to the fight against TB in her professional life of 40 years. The prize was awarded in December 2015 in Cape Town during the 46th Union World Conference on Lung Health. [http://www.stoptb.org/global/awards/kochon/awardees/2015.asp](http://www.stoptb.org/global/awards/kochon/awardees/2015.asp)

The 2015 Kochon Prize winners

PRABHA MAHESH SHANKAR “TB Journeys”

“I went through a period of turmoil when I had TB. I was afraid of stigma and didn’t have the confidence or courage to face anyone. My family helped me cope, but people at my workplace came to know and I was isolated. I was so despairsed that I missed a few doses. We are not cases. We’re human beings. Health workers and government authorities need to be more sensitive to the needs and feelings of people with TB.”

PRAKASH KUMAR VELASHEKAR

“I was isolated. I was so despaired that I missed a few doses. We are not cases. We’re human beings. Health workers and government authorities need to be more sensitive to the needs and feelings of people with TB.”

PRABHA MAHESH SHANKAR “TB Journeys”

The overall goal of Round 7 is to build recognized civil society / community networks that represent, support and are accountable to communities who can partner with one another and successfully engage in the national TB response. Out of 482 that applied, 10 proposals (6 from Africa, 2 from Eastern Europe and 2 from Eastern Europe and Central Asia) were recommended for funding. The grantee and respective country profiles can be found here: [http://www.stoptb.org/global/awards/cfcs/about.asp](http://www.stoptb.org/global/awards/cfcs/about.asp).

Grants are being implemented in two phases. To implement Phase II activities, grantees, using tools developed by the Stop TB Partnership, conducted exercises to map the community response, the actors and the gaps in geographic and service delivery, according to the six core components of a functional community system with a focus on key populations. Given that the focus of Round 7 is to build functional networks, a novel evaluation framework using both qualitative and quantitative methodologies is being implemented. The process and calibre of collaboration is being evaluated. Independent baseline assessments have taken place in all ten countries and end of project assessments will take place in the last two months of grant implementation. Phase I for all grantees is coming to an end, and project deliverables (Directory of CSOs, Matrices of Community Response, Gap in Services and Populations documented, CSO network identified, Network Engagement Plan and Work-plan for Phase II, which aligns with the identified gaps) are currently being finalized and shared with key national stakeholders, including National TB Programs. The Stop TB Partnership is in the process of developing webpages for grantees and compiling a mid-term impact report.

The 2015 Kochon Prize theme, voted on and chosen by Stop TB partners, focused on unrecognized/unsung heroes working in TB.

Out of 482 that applied, 10 proposals (6 from Africa, 2 from Eastern Europe and Central Asia) were recommended for funding. The grantee and respective country profiles can be found here: [http://www.stoptb.org/global/awards/cfcs/about.asp](http://www.stoptb.org/global/awards/cfcs/about.asp).

Grants are being implemented in two phases. To implement Phase II activities, grantees, using tools developed by the Stop TB Partnership, conducted exercises to map the community response, the actors and the gaps in geographic and service delivery, according to the six core components of a functional community system with a focus on key populations. Given that the focus of Round 7 is to build functional networks, a novel evaluation framework using both qualitative and quantitative methodologies is being implemented. The process and calibre of collaboration is being evaluated. Independent baseline assessments have taken place in all ten countries and end of project assessments will take place in the last two months of grant implementation. Phase I for all grantees is coming to an end, and project deliverables (Directory of CSOs, Matrices of Community Response, Gap in Services and Populations documented, CSO network identified, Network Engagement Plan and Work-plan for Phase II, which aligns with the identified gaps) are currently being finalized and shared with key national stakeholders, including National TB Programs. The Stop TB Partnership is in the process of developing webpages for grantees and compiling a mid-term impact report.

The overall goal of Round 7 is to build recognized civil society / community networks that represent, support and are accountable to communities who can partner with one another and successfully engage in the national TB response. Out of 482 that applied, 10 proposals (6 from Africa, 2 from Eastern Europe and Central Asia) were recommended for funding. The grantee and respective country profiles can be found here: [http://www.stoptb.org/global/awards/cfcs/about.asp](http://www.stoptb.org/global/awards/cfcs/about.asp).

Grants are being implemented in two phases. To implement Phase II activities, grantees, using tools developed by the Stop TB Partnership, conducted exercises to map the community response, the actors and the gaps in geographic and service delivery, according to the six core components of a functional community system with a focus on key populations. Given that the focus of Round 7 is to build functional networks, a novel evaluation framework using both qualitative and quantitative methodologies is being implemented. The process and calibre of collaboration is being evaluated. Independent baseline assessments have taken place in all ten countries and end of project assessments will take place in the last two months of grant implementation. Phase I for all grantees is coming to an end, and project deliverables (Directory of CSOs, Matrices of Community Response, Gap in Services and Populations documented, CSO network identified, Network Engagement Plan and Work-plan for Phase II, which aligns with the identified gaps) are currently being finalized and shared with key national stakeholders, including National TB Programs. The Stop TB Partnership is in the process of developing webpages for grantees and compiling a mid-term impact report.

The overall goal of Round 7 is to build recognized civil society / community networks that represent, support and are accountable to communities who can partner with one another and successfully engage in the national TB response. Out of 482 that applied, 10 proposals (6 from Africa, 2 from Eastern Europe and Central Asia) were recommended for funding. The grantee and respective country profiles can be found here: [http://www.stoptb.org/global/awards/cfcs/about.asp](http://www.stoptb.org/global/awards/cfcs/about.asp).

Grants are being implemented in two phases. To implement Phase II activities, grantees, using tools developed by the Stop TB Partnership, conducted exercises to map the community response, the actors and the gaps in geographic and service delivery, according to the six core components of a functional community system with a focus on key populations. Given that the focus of Round 7 is to build functional networks, a novel evaluation framework using both qualitative and quantitative methodologies is being implemented. The process and calibre of collaboration is being evaluated. Independent baseline assessments have taken place in all ten countries and end of project assessments will take place in the last two months of grant implementation. Phase I for all grantees is coming to an end, and project deliverables (Directory of CSOs, Matrices of Community Response, Gap in Services and Populations documented, CSO network identified, Network Engagement Plan and Work-plan for Phase II, which aligns with the identified gaps) are currently being finalized and shared with key national stakeholders, including National TB Programs. The Stop TB Partnership is in the process of developing webpages for grantees and compiling a mid-term impact report.
Technical support for engaging communities in national planning and country dialogues

Regional Workshops

Five regional workshops were hosted in partnership with key regional civil society partners to ensure civil society and communities are trained on the integration of community, rights and gender in the context of TB.

A. Dakar, Senegal, April 2016 – HIV key populations estimations. This was a Global Fund-funded workshop that the Stop TB Partnership presented in. The purpose of the workshop was to help countries learn about and develop programmatic mapping of HIV key populations. After the TB presentation, several countries included prisoners and miners. Their proposals will be submitted to the Global Fund CRG Team.

B. Abuja, Nigeria, May 2016 – Stop TB Partnership Nigeria. This Stop TB Partnership workshop was in collaboration with other partners organized the first National TB Conference held at Federal Capital Territory in Abuja, Nigeria. The conference attracted many national and international stakeholders and was held in 2015. The Partnership is continuing to work on strengthening the CCMs and is in the process of developing a TB specific e-module for CCMs.

C. New York, USA, June 2016 – UN high level meeting on HIV/AIDS

Supporting the participation of communities in programme reviews

Nine countries, Armenia, Cape d’Ivoire, India, Kenya, Kyrgyzstan, Pakistan, Philippines, Tanzania and Zimbabwe received support that enabled community members to participate in TB programme reviews. Guidance on how to review the community’s contribution in the TB response was also provided.

Peer Reviews

During this reporting period, community input was sought through concept notes. In addition to this, Stop TB staff also reviewed and provided feedback on concept notes received through the TB Situation Room, Global Fund portfolio managers and CCMS.

New York, 19-20 September 2016

What we achieved

Strengthening TB CCMS

In June 2016, 38 members representing TB communities from 21 countries met in Manila, Philippines during a workshop aimed to build the capacity of CCM representatives and advocates to effectively represent their constituencies in their country decision-making mechanisms (CCMs).

The Stop TB Partnership, the Global Fund, and the International HIV/AIDS Alliance collaborated to organize this workshop. The workshop focused on the need to change the approach for impactful action, strongly underlining that the WHO End TB strategy milestones will be missed if current efforts continue without a paradigm shift as articulated by the Stop TB Partnership’s Global Plan to End TB. The workshop was followed on from the first successful CCM workshop which was held in 2015. The Partnership is continuing to work on strengthening the CCMS and is in the process of developing a TB specific e-module for CCMS.

End TB and AIDS by 2030

Forty people, including community advocates from ten countries, gathered in Bangkok for a workshop in late June 2016 to discuss gaps, challenges and opportunities around Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) programming from a human rights and gender perspective. The participants, mostly women, included a wide range of people living with or affected by HIV, TB or malaria. The workshop was co-organized by WomenGlobalFund (WAGF) and the Communities Delegation to the Board of the Global Fund, supported by the Stop TB Partnership and the Global Fund, and hosted by APACSO.

Gender

The Stop TB Partnership collaborated with UNAIDS and the Global Fund to adapt the existing Gender Assessment Tool for HIV/AIDS to include TB in country gender analysis.

The tool underwent peer review by a cross cutting team of gender experts from communities and technical agencies and launched on 1 July 2016. More than 20 TB/HIV community advocates participated in an orientation workshop on this tool last year. The piloting process has been completed in Lesotho and the TB/HIV gender analysis has been considered during the TB/HIV concept note development process. In addition to the Gender Assessment Tool, a gender interventions document is being developed to help as a guide for TB gender sensitive programming.

As the demand for gender analysis picks up and more and more countries are looking to incorporate gender sensitive interventions in their programming, Stop TB organized a workshop to train a cadre of consultants to use the TB/HIV Gender Assessment Tool. The workshop was organized in collaboration with the Global Fund and UNAIDS and held in Johannesburg, South Africa in July 2015. Facilitators who were involved in the piloting of the tool in Lesotho led the sessions and trained twenty-two consultants to conduct gender assessments. The workshop also strengthened the capacity of TB activists and gender equality advocates to engage at country level with TB national planning processes including those linked to the Global Fund and its new funding model (NFM) from a gender equality perspective.

The tool has now been also been conducted in Niger and Namibia. Results from these assessments have not been approved by the countries and so we cannot share the data as yet. Namibia will hold a country workshop to validate the findings and recommendations this month. The recommendations from the Niger assessment are now with the Global Fund who will determine which recommendations can be added to the next grant. Lessons learned are that it is crucial to get in-country support for the assessment. The Niger assessment, for example came from the GAC and it took a lot of work to get the country programs on board. The Namibia assessment was led by UNAIDS in country and this helped in getting the programs involved and engaged.

We have been working closely with NGOS at all levels of the Global Fund and a broader TB community including technical
Human rights

In collaboration with KELIN and the University of Chicago, the Partnership developed a strategy on TB and human rights with the long-term goal to develop and implement a human rights-based approach to TB at the global, regional, national and local levels.

To this end, building on the experience of the Judicial Workshops in New Delhi and Nairobi, we are also working with UNDP and have developed a legal environment assessment (LEA) tool which will be piloted this year, funds permitting. The LEA aims to build national capacity for facilitating an inclusive and participatory process for developing a human rights framework for TB and reviewing national laws and policies to align them with this framework. However, in the broader context of national efforts to address TB risk and epidemics, LEAs play an important role in identifying multiple contextual issues impacting access to diagnosis, treatment and care for those who are most vulnerable to the two diseases.

Key Populations

As an outcome of the first meeting of key populations held in Bangkok in November 2015, a set of nine mini briefs were developed in order to enable advocates, program implementers, and key stakeholders to understand the determinants that prevent key populations from accessing prevention, diagnosis, treatment, care, and support services.

Building regional networks of people affected by TB

The Stop TB Partnership, together with partners organized the first regional workshop on TB community mobilization in the Eastern Europe and Central Asia regions in order to leverage their expertise so that they can become advocates who can be deeply engaged in the fight in their countries to end TB.

TBpeople: Mobilizing the community of people with experience of TB in Eastern Europe and Central Asia

In June 2016, the Stop TB Partnership, with the support of USAID in collaboration with RESULTS UK and TB Europe Coalition hosted the first regional workshop of people with experience of TB in Bratislava, Slovakia.

Global Coalition of TB Activists (GCTA)

In coordinating efforts and activities of its global network of civil society members, the Global Coalition of TB Activists (GCTA) held meetings and events around the community space during the 48th Union World Lung Conference 2016 held in Cape Town ensuring community engagement. Members of the GCTA have been actively engaging and participating in multiple fora ensuring the voice of the community is heard and being included in policies and plans.

"At the beginning I felt ashamed so I always said to my friends that I was just ill. There was a very horrible doctor who told me 'You have TB (Eres una tuberculosa). Why do you want to live?' But others gave me their support and gave me reasons to keep on breathing. We need to promote empathy between health workers and people with TB. There is an urgent need for a change in the attitude toward people with TB, we are not numbers, but human beings, and need to be treated with kindness and respect. I want to empower civil society to defend their rights."

EVA LIMACHI SALGUEIRO
"TB Journeys"
Stop TB Partnership Working Groups

The Secretariat highlights the achievements of the Working Groups through biannual bulletins (accessible here: http://stoptb.org/wg/)

Stop TB Partnership

Working Groups

The annual meeting of the TB INFECTION CONTROL SUBGROUP was held on the margins of the Union World Lung Conference in December and the group changed their name to The End TB Transmission Initiative (ETT). The group have developed and are implementing their strategic plan (2015-2018) in which they intend to end TB transmission by:

a. Advocating for TB infection prevention and control as a worldwide priority, and achieve those goals by collaborating with TB partners, decision-makers of donor countries, civil society, and other stakeholders.

b. Helping to build and disseminate the evidence base supporting best TB transmission control practices and tracking worldwide implementation.

c. Helping professionals develop, implement, and evaluate best practices through research and disseminate what works.

d. Engaging civil society in supporting a global movement to prevent TB transmission everywhere.

The GLL WORKING GROUP welcomed three new members for the 2016-2017 term: Dr Lucilaine Ferrazoli, Dr Nguyen Van Hung and Dr Elisa Tagliani. Dr Ferrazoli is a research scientist in the TB and Mycobacteriology Laboratory of the Adolfo Lutz Institute in Sao Paolo, Brazil. Dr Hung is the Head of Department at the National TB Reference Laboratory at the National Lung Hospital in Hanoi, Vietnam. Dr Tagliani is a research scientist at the Emerging Bacterial Pathogens Unit of the San Raffaele Scientific Institute in Milan, Italy (SRL Milan).

The NEW DIAGNOSTICS WORKING GROUP and its Task Force on tests for progression of LTBI to active disease have recently launched an online consultation to gather input on a draft Target Product Profile (TPP) for a test of progression of latent tuberculosis infection (LTBI).

THE CHILDHOOD TB SUBGROUP have provided technical assistance to Nepal, Sri Lanka, Myanmar, have been involved in the Philippines and Zimbabwe’s programme reviews and have participated in various meetings, including the Pan African Thoracic Society Lung Conference, the UNICEF meeting on integration of childhood TB in MCH, HIV and Nutrition programmes, the IMPACT annual meeting, and the Union Europe Region meeting. The core team is seeking new members representing the WHO South East Asia and Western Pacific regions and the Subgroup will also elect a new chair after the annual subgroup meeting in October.

WORLD TB DAY

OUR GOAL IS TO END THE GLOBAL TB EPIDEMIC WITHIN 1 GENERATION

UNITE TO END TB
In December 2015, Minister Motsoaledi and I were in Tokyo to participate in the International Conference on Universal Health Coverage (UHC) and the Global Fund’s Fifth Replenishment Preparatory Meeting. Japan hosted the UHC conference, ahead of the G7 Summit, which was attended by nearly 300 people, including Japan’s Prime Minister Shinzo Abe. During one of the panel sessions, I was able to allocate cycle. During the high-level panel session with the Secretary-General of the Bill & Melinda Gates Foundation, Marie-Claude Bibeau, Canada’s Minister of Interna-
tional Development and La Francophone, and Dab Dugan, Chief Exec-
tive Officer (RED), and Minister Motsoaledi highlighted the need for in-
novations in address-
ing TB and malaria.

The Stop TB Partnership ensures the voice of the TB community at large is well-re-
presented in Global Fund pro-
cesses:

The Stop TB Partnership Secretariat is engaged in several areas of collaboration with the Global Fund Secretariat, Board, Board committees and partners. The diagram below shows the multiple levels of engagement with the Global Fund to ensure TB friendly funding policies and allocations and maximizing impact of the Global Fund grants.

Our Partners
The Directory of Partners continues to be updated and currently boost a membership of over 1528 as of end August 2016.

The Operational Strategy mandated the Secretariat to conduct an annual sur-
vey with partners in order to evaluate their satisfaction with the services and support provided by the Secretariat.

The 2016 survey is currently being conducted and so far, we have 115 respond-
ents. The survey is conduc-
ted to collect feedback and ideas on the services that partners want the Sec-
retariat to provide, and to evaluate the successes and pitfalls of our work moving forward.

In Partnership with
the Global Fund to
Fight AIDS, TB &
Malaria
The Stop TB Partnership Secretariat is engaged in several areas of collaboration with the Global Fund Secretariat, Board, Board committees and partners. The diagram below shows the multiple levels of engagement with the Global Fund to ensure TB friendly funding policies and allocations and maximizing impact of the Global Fund grants.

In Partnership with
the Global Fund to
Fight AIDS, TB &
Malaria
The Stop TB Partnership Secretariat is engaged in several areas of collaboration with the Global Fund Secretariat, Board, Board committees and partners. The diagram below shows the multiple levels of engagement with the Global Fund to ensure TB friendly funding policies and allocations and maximizing impact of the Global Fund grants.

The Stop TB Partnership
Secretariat is engaged in several areas of collaboration with the Global Fund Secretariat, Board, Board committees and partners. The diagram below shows the multiple levels of engagement with the Global Fund to ensure TB friendly funding policies and allocations and maximizing impact of the Global Fund grants.
TB REACH: Supporting innovation in TB detection and care

The period covered by this report was a time of transition for the TB REACH initiative, but also of great success and forward momentum.

On 31 March 2016, the initial 2010-2015 TB REACH award from Global Affairs Canada came to an end. Fifty-six projects which TB REACH was supporting to deliver innovative approaches and technologies in 30 countries also came to a close. During the reporting period, these projects collectively treated over 206,000 people with TB, over 193,000 people were tested using the Xpert MTB/RIF assay, which represents a 17.5% increase in the number of tests performed compared to testing between the same dates last year. During this reporting period, 47 cash disbursements to grantees were made, totaling of USD 2,306,334.

TB REACH had great success linking successful projects totaling of USD 2,306,334. During Waves 1-4, TB REACH awarded USD 3.4 million to Indus Hospital in Karachi, Pakistan to pilot and evaluate different activities focused on engaging the private healthcare sector. Many of these approaches proved highly impactful and during the reprogramming of the Global Fund grant to Pakistan and with Stop TB Partnership Secretariat support in early 2016, Indus Hospital became the Primary Recipient for private healthcare sector engagement in two provinces and was awarded USD 40 million to scale up the TB REACH approaches piloted around childhood TB, private sector engagement and new diagnostics.

In Moldova, TB REACH began supporting the PSS Centre to use GeneXpert technology as a replacement for smear microscopy testing in 2011. This resulted in an 84% reduction in time to appropriate treatment for MDR-TB patients. Going forward these testing activities will be supported in Moldova by both domestic funds and the Global Fund to cover the country using Xpert as a first test and becoming one of the few countries following the lead of South Africa. In South Africa, IRD and the Aurum Institute piloted a mHealth app custom-built for Android phones to facilitate screening of TB, HIV/AIDS and silicosis in mine labour-sending communities. In May 2016, the Government of Canada announced that it was renewing its pledge for the TB REACH initiative with a second five-year, CAD 85 million award. The Bill and Melinda Gates Foundation also confirmed its initial conditional pledge of USD 5 million (announced in the previous Coordinating Board Report) and increased the commitment by 40% to USD 7 million. Finally, the Indonesia Health Fund, which is comprised of eight Indonesian business leaders, pledged USD 15 million to support TB REACH projects in Indonesia. With these commitments in place, TB REACH moved quickly to launch a new funding cycle hosting a large Partners consultation meeting followed by the Program Steering Group. A strategic partnership with the McGill International TB Centre was agreed upon to help future projects with implementation research and results dissemination. On 2 August, TB REACH launched the Wave 5 call for proposals and will select new grantees by mid-December.

Delivering quality assured anti-TB medicines, diagnostics, and knowledge: Global Drug Facility (GDF)

Key milestones achieved by GDF since last report to the Board, November 2015

Active market shaping for TB products

As per outcomes of Invitation to Bid (ITB) published in February 2016, GDF secured the supply of second-line TB medicines to respond to the goals of the Global Plan to End TB, including the introduction of new medicines and regimens.

Figure 1: MDR-TB medicines cost reductions
Four new suppliers participated in this ITB and were considered eligible for the supply of anti-TB medicines. A major price decrease has been achieved for Linazolid due to a new generic product manufacturer entering the market compared to last year. Additional suppliers for high demand products are now on board including two additional suppliers for kanamycin. However, GDF is still facing some challenges in the manufacturing environment such as an increase in the cycloserine price compared to last years bidding due to a dramatic drop in demand and prices in the last bidding process, at the beginning of 2016, GDF was still challenged by the limited availability of certain key drugs such as Kanamycin and Clofazimine due to manufacturers’ production capacity.

The GDF actively managed the supply to allocate these drugs to countries based on continuous communication with NTPs, analysis of in-country stock levels, actual number of patients enrolled, orders in the pipeline, and enrollment plans; no stock-outs, treatment interruptions or delayed enrollment were reported. GDF used its Flexible Procurement Fund to provide financial options to the GDF client countries to eliminate delays related to payments for orders. Through this mechanism, countries can place orders without having to issue an upfront payment and therefore avoid treatment interruption. In 2016, two countries (Lesotho and Kiribati) benefited from the USAID Flexible Procurement Fund for a total amount of USD81,250.

Memorandum of Understanding between Global Fund and Stop TB Partnership’s GDF

In June 2016, Stop TB Partnership signed a Memorandum of Understanding (MoU) with the Global Fund to Fight AIDS, Tuberculosis and Malaria to optimize access to TB health products and pharmaceutical services in countries receiving Global Fund financing for TB.

The Global Fund and Stop TB Partnership recognize the potential for a more strategic partnership between the Global Fund and Stop TB Partnership’s GDF and the mutual benefits to be gained through structured, collaborative engagement to optimize TB markets and improve the supply chain of TB health products to countries supported by the Global Fund. Under the agreement, the Global Fund and Stop TB/ GDF will align pooled procurement and market shaping strategies, demand forecasting, and continuous performance improvement activities.

Strategic procurement solutions for TB medicines and diagnostics

Despite the improved availability of certain SLD medicines and decrease in prices in the last bidding process, at the beginning of 2016, GDF was still challenged by the limited availability of certain key drugs such as Kanamycin and Clofazimine due to manufacturers’ production capacity.

The primary objective of the new SRS is to decrease time from the time the order is placed (i.e. payment received and contract/quote signed) to the delivery to destination. As the new SRS tool is implemented, several sub-objectives will also be achieved as follows:

a. STREAMLINE PRODUCTION to better assure adequate supply of drugs,

b. LEVERAGE "VOLUME-BASED" UNIT PRICES to better meet supplier conditions and batch sizes,

c. AVOID STOCK OUTS IN COUNTRIES whereby drug-resistant TB cases can be treated on time preventing extensive-resistant cases from evolving,

d. ASSIST NATIONAL TB PROGRAMS in the uptake of new TB regimens recommended by WHO,

e. ALLOW GDF TO PROVIDE MEDICINES in one delivery for full MDR-TB/MDR-TB shorter-course regimens.

The new SRS will have improved information technology through dedicated human support and software, allowing more efficient operations and coordination for GDF and its procurement agent. Two important tools - the product and country profiles - are under development to provide the information required for SRS-related decision making, including the selection and prioritization of TB medicines and quantification for SRS product replenishment.

First meeting of TB Product Procurement and Market Shaping Working Group

On 27 July 2016, the Stop TB Partnership’s GDF convened the first meeting of the TB Product Procurement and Market Shaping Working Group in Washington D.C.

This Working Group will serve to bring together procurers and key stakeholders, including people affected by TB and advocates, in order to address common procurement and market shaping challenges inherent to the fragile TB markets. Twenty-seven participants from USAID, CHAI, GDF, Global Fund, TB Alliance, MSF, MSH, TAG, UNDP, UNITAID, USP, WHO, TB advocates and experts attended the meeting.

The overall purpose of this Working Group will be to improve supply security and affordability of quality-assured TB products. This will be done through strategic management of demand, streamlining product selection to address market fragmentation, coordination of procurement, and sending clear signals to suppliers on products and formulations in need of development and support.

Development of a new efficient Strategic Rotating Stockpile (SRS) operational project plan

To improve its procurement and supply operations and align with GDF strategic objectives, GDF has developed a new SRS operational project plan.

WHAT WE ACHIEVED
Saving lives by expanding access to high quality TB treatments.

Since its inception in 2001, GDF delivered a total of 26.5 million adult FLD patient treatments, 1.53 million FLD pediatric patient treatments and 218,466 SLD treatments as of June 2016 (figure 2).

In the first half of 2016, the total value of orders placed was USD 75 million, of which 45% was for second line anti-TB medicines (SLDs), 37% for first line anti-TB medicines (FLDs) and 18% for diagnostics.

Figure 2: Cumulative patient treatments delivered

In the first half of 2016, the healthcare workers did little to help me understand the disease. I read everything I could find on the internet about TB, from scientific articles to scientific research and country strategies. I then knew everything about TB, from the physiology of the Mycobacteria to dosages and spectrums of side effects for drugs. Once informed, I was able to inspire trust in the healthcare workers. I became a target for sympathy and astonishment, not fear and stigmatization. I was cured in 2012. As an activist, I now have frequent opportunities to provide feedback on the quality of care.

Valeria Istrati

TB Journeys

Quality assurance

As of June 2016, the GDF FLD portfolio consisted of 27 quality assured products supplied by 15 manufacturers. The SLD portfolio comprised of 50 products supplied by 31 manufacturers, including medical supplies and water for injections. This represents all groups of medicines currently recommended by WHO for treatment of drug susceptible and resistant forms of TB.

During this reporting period, in response to the new TB guidelines, new products were added to the GDF catalogue—Amoxiclav, 1g tab from Madranch, Kanamycin 0.5 g solution & powder from Shanghai Harvest and Macleods, Meropenem from Viyanix, Rifaxipentine 150mg tab from Sanofi in response to WHO recommendations on short-course treatment of Latent TB Infection (LTBI), the new innovator product, Delamanid 50mg tab from Otsuka, generic Linezolid 600mg tab from Tava and new pediatric formulations with optimized dosing from Macleods. Dossiers with relevant documentation were gathered from potential suppliers of most demanded products and shared with the Global Fund to include newly added products on the PSM list, which facilitates procurement of these products through Global Fund grants.

Capacity building and technical assistance

In 2016, GDF is revamping its technical assistance strategy to align with new GDF strategic objectives and respond to increased demand for GDF technical leadership in strengthening pharmaceutical management systems in countries and establishing an efficient information system and early warning to ensure uninterrupted access to quality-assured TB products.
Bedaquiline Donation Program

GDF has continued to implement the BDQ donation program that was made available through an agreement between USAID and the Johnson & Johnson affiliate, Janssen Therapeutics.

The GDF shares monthly reports of new MDR-TB drugs (bedaquiline and delamanid) with the Drug-Resistant TB Scale-Up Treatment Action Team (DR-TB STAT) and posts these reports on the Stop TB website. GDF participated in the DR-TB STAT members’ monthly calls to discuss progress and solve problems around national and global challenges encountered during new drug introduction and scale-up. The GDF renegotiated procurement agent fees for bedaquiline, moving from a fee based upon “market prices” to a flat fee. This GDF-led negotiation resulted in savings of more than USD 1 million to national TB programs. By the end of 2016, EDQ shelf life will be extended from two years to three years and the product will be added to SRS. As of September 2016, 40 countries have drafted or actually placed orders for 4623 bedaquiline patient treatments through GDF, of which 1723 bedaquiline patient treatments were delivered.

Introduction of Delamanid

GDF was the first organization to come to agreement with Otsuka on access to delamanid, another new, life-saving medicine for MDR-TB.

On 24 February, 2016, GDF held a high-level discussion in Bangkok, Thailand alongside the Joint WHO SEA-RR-WPRO-HQ “Experience sharing workshop on the introduction of new drugs for DR-TB in the WHO South-East Asian and Western Pacific Regions.” The Otsuka-StopTB/GDF MoU and the official launch of delamanid via GDF were announced at this event. It was a rare event where participants gathering for a WHO and private sector meeting had the opportunity to engage directly with the scientists researching and producing new medicines and a rich dialogue ensued.

In order to ensure immediate availability and delivery of this new life-saving medicine to countries, GDF will be adding delamanid to SRS. GDF coordinated production planning, demand estimates and strategic allocation of DLM with the Procurement Agent and manufacturer, and provided technical assistance to countries to improve forecasts, quantification, and forecasting. This has helped to increase interest and accelerate the uptake as it has provided a good incentive for countries to plan their transition to the new formulations.

Introduction/uptake of new pediatric formulations

The new child-friendly, adequately-dosed pediatric formulations were launched on 2 December 2015 during the Union Conference.

GDF worked closely with its partners, including the TB Alliance, WHO, Global Fund, Challenge TB and SARI for the launch of the new pediatric formulations. In December 2015 during the Union Conference, GDF co-facilitated a symposium, “Improving Access to Appropriate Pediatric TB Medicines” to share lessons learned from previous involvement with TB paediatrics and discuss key supply challenges, the need for action at the country level, and how to procure new pediatric formulations from GDF.

In January 2016, Stop TB/ GDF together with WHO and the Global Fund released a technical briefing note, “Technical Step process to switch to new pediatric formulations,” aiming at guiding the countries in the transition phase.

GDF also played a key role in providing thought leadership and technical advice on determining the appropriate number of formulations, which led to producing only two formulations instead of six formulations that were initially planned, in order to prevent further fragmentation of the paediatric market. Prior to agreeing to list the new pediatric formulations in the GDF catalogue, GDF held multi-partner discussions that led to additional interventions and price reductions in line with GDF’s suggestions and, ultimately, contributed to a successful global launch of the new formulations. Upon a new price agreement, the GDF worked with the supplier to draft and sign a long-term agreement to distribute the new formulations via the GDF and negotiate with the supplier to agree on GDF’s terms with no minimum order quantity. The new formulations were listed in the GDF catalogue in March 2016. To promote the roll-out of the new pediatric formulation, GDF is proactively offering its technical assistance in coordination with WHO and other partners through the missions, workshops and trainings for the National TB programs and the national paediatric community in supply planning for phase-in/phase-out, quantification, and forecasting. This has helped to increase interest and accelerate the uptake as it has provided a good incentive for countries to plan their transition to the new formulations.

Diagnostics

Since 2008, GDF has contributed to active case-finding by procurement diagnostics worth USD 135 million to more than 82 countries.

From January to June 2016, 64 orders have been placed with suppliers and 149 shipments delivered to countries (total value of USD 13.9 million). The median lead-time is 25 days from order placed with suppliers to first shipment arrival. In 2015, all diagnostics became available for direct procurement. While the majority of orders were financed through grants (UNITAID and TB REACH) in 2015, the direct procurement has increased up to 82% of total value of diagnostics procurement this year. Even after grants ended between 2015 and 2016, demand for diagnostics is sustained through direct procurement by countries. It demonstrates the important added value of grant projects to scale up new diagnostics in countries and the development of a robust GDF portfolio of TB diagnostic commodities.

“On this World Tuberculosis Day, I call on leaders across Government, civil society and the private sector to unite to end tuberculosis. Together we can win the fight and end the TB epidemic by 2030.”

[Ban Ki-Moon, United Nations Secretary-General]
Board Members

The Stop TB Partnership Coordinating Board provides leadership and direction, monitors the implementation of agreed policies, plans and activities of the Partnership, and ensures coordination among Stop TB Partnership components.

**CHAIR**

- **Dr Aaron Motsoaledi**
  Minister of Health, South Africa

**VICE CHAIR**

- **Dr Jeanette Kagame**
  Minister of Health, Rwanda

**DONORS**

- **Ms Cheri Vincent**
  Lead Health Specialist, World Bank
- **Ms Mary Morin**
  Lead Health Specialist, WHO
- **Mr Aaron Motsoaledi**
  Minister of Health, South Africa

**TB AFFECTED COUNTRIES**

- **Ms Li Bin**
  Ministry of National Health and Family Planning Commission of China
- **Mr Navdeep Rinsa**
  Joint Secretary, Ministry of Health and Family Welfare, India
- **Dr Nazira Abdula**
  Deputy Ministry of Health, Mozambique

**DEVELOPING COUNTRY NGO**

- **Mr Michel Sidibe**
  Executive Director, United Nations Programme on HIV/AIDS (UNAIDS), Switzerland
- **Dr Mark Dybul**
  Executive Director, The Global Fund to Fight AIDS, Tuberculosis & Malaria, Switzerland
- **Mr Latif Marmara**
  Executive Director, UNITAID

**TECHNICAL AGENCIES**

- **Dr Susan Maloney**
  Global TB Coordinator, Centers for Disease Control and Prevention (CDC), United States of America
- **Dr Paula Fujiwara**
  Scientific Director, International Union Against Tuberculosis and Lung Disease (The Union), France
- **Dr Kitty von Wrazenbeek**
  Executive Director, KNCV Tuberculosis & Malaria, The Netherlands

**ORGANIZATIONS**

- **Mr Dr. Keith Warren**
  Global TB Coordinator, Centers for Disease Control and Prevention (CDC), United States of America
- **Mr Timur Abdullaev**
  Executive Director, KNCV Tuberculosis & Malaria, The Netherlands

**COUNTRY NGO**

- **Mr Miriam Schneidman**
  Executive Director, RESULTS USA
- **Dr Celeste Kinsey**
  Executive Director, RESULTS UK

**HOST ORGANIZATION**

- **Ms Abigail Grady**
  Global TB Coordinator, Centers for Disease Control and Prevention (CDC), United States of America

**PRIVATE SECTOR**

- **Mr Evan Lee**
  Executive Director, RESULTS USA

**FOUNDATIONS**

- **Ms Erika Arthun**
  Director, Global TB Programme World Health Organization Switzerland
- **Ms Miriam Schneidman**
  Lead Health Specialist, World Bank, United States of America
- **Mr Aaron Motsoaledi**
  Minister of Health, South Africa

**WORKING GROUPS**

- **Mr Dr. Keith Warren**
  Chair, Working Group on TB Vaccines United States of America
- **Mr Charles Daley**
  Chair, Global Drug Initiative Working Group, United Kingdom

**DEVELOPED COUNTRY NGO**

- **Mr Austin Obi-efuna**
  Executive Director, AFRO Global Alliance, Ghana

**UNITARY AND TECHNICAL AGENCIES**

- **Mr Dr. Keith Warren**
  Global TB Coordinator, Centers for Disease Control and Prevention (CDC), United States of America

**PRIVATE SECTOR**

- **Mr Aaron Motsoaledi**
  Minister of Health, South Africa

---

**Crossword Puzzle**

How well do you know TB?

1. Microscopic living organisms, usually one-celled, that can be found everywhere.
2. Refers to unequal opportunities, social exclusion, unemployment, or precarious employment and other social, cultural, political, and economic factors that make a person more susceptible to TB.
3. TB infection that has spread outside of the lungs.
4. Provides adolescents and adults with little protection against TB, but is given to infants and small children in countries where TB is common, as it can prevent some of the most severe forms of TB in children.
5. They are designed to address an unacceptable gap in the provision of TB care.
6. Excessive sweating during sleep, one of the main symptoms of TB.
7. Hold each year to build public awareness for tuberculosis, falls on 24 March.
8. A drug used to treat bacterial infectious.
9. It is a condition in which TB bacteria are alive but inactive in the body. People affected have no symptoms; they do not feel sick, cannot spread TB bacteria to others.
10. Curable disease known to humanity for thousands of years that cannot spread TB bacteria to others.
11. It is a condition in which TB bacteria are alive but inactive in the body. People affected have no symptoms; they do not feel sick, cannot spread TB bacteria to others.
12. A symbol designed to represent the TB community’s commitment to ending TB.
13. Refers to the systematic identification of people with active TB in a predetermined target group by application of tests, examinations or other procedures that can be applied rapidly.
14. Refers to any form of arbitrary distinction, exclusion or restriction affecting a person, usually but not only by virtue of an inherent personal characteristic or perceived belonging to a particular group.
15. Phlegm coughed up from deep inside the lungs.
16. Policies, programs, or training modules recognize that both women and men are actors within a society.
17. Disease caused by a strain of TB bacteria that is resistant to at least isoniazid and rifampin.
18. A test to see whether there are TB bacteria in an individual’s sputum/phlegm or other body fluids.
19. Is derived from the Greek meaning “a mark or a stain”. It can be described as a dynamic process of devaluation that significantly discredit an individual in the eyes of others.
20. People who are vulnerable, underserved or at-risk of TB infection and illness.
21. Disease caused by a strain of TB bacteria that is resistant to isoniazid and rifampin, as well as fluoroquinolones and at least one of the three injectable second-line drugs.
22. Abbreviation for mobile health, a term used for the practice of medicine and public health supported by mobile devices.
10 MILLION

LIVES COULD BE SAVED FROM DYING OF TB IN THE NEXT 5 YEARS
Implement the Global Plan to End TB 2016-2020

UNITE TO END TB

Stop TB Partnership